CBAY - CymaBay to raise $150M to primarily fund clinical trials
2023-09-11 06:07:59 ET
- CymaBay Therapeutics ( NASDAQ: CBAY ) has commenced an underwritten public offering of an aggregate of $150M of its common stock and pre-funded warrants.
- The underwriters has a 30-day option to purchase up to an aggregate of an additional 15% of the shares of its common stock offered in the public offering, including shares of common stock underlying the pre-funded warrants.
- Net proceeds will be used to fund ongoing development of seladelpar, including clinical trials targeting market expansion, and for working capital and general corporate purposes.
- Source: Press Release
For further details see:
CymaBay to raise $150M to primarily fund clinical trials